A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.

NCT04179409 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

3

Enrollment

OTHER

Sponsor class

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG: Amondys 45
DRUG: Exondys 51
DRUG: Vyondys 53

Sponsor

Kevin Flanigan

Collaborators

[object Object]